May 14, 2019
Daiichi Sankyo’s hypertension treatment Minnebro (esaxerenone) went on sale in Japan on May 13 following its approval in January and listing in late February. Minnebro, a non-steroidal selective novel mineralocorticoid receptor blocker, was identified through the company’s collaboration with US...read more